Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 48 | 2023 | 134 | 13.630 |
Why?
|
| Anti-Asthmatic Agents | 15 | 2022 | 25 | 4.230 |
Why?
|
| Hypersensitivity | 7 | 2023 | 46 | 2.720 |
Why?
|
| Physicians | 6 | 2022 | 112 | 2.640 |
Why?
|
| Burnout, Professional | 4 | 2022 | 39 | 2.280 |
Why?
|
| Adrenal Cortex Hormones | 11 | 2023 | 102 | 2.140 |
Why?
|
| Patient Education as Topic | 7 | 2021 | 140 | 1.950 |
Why?
|
| Telemedicine | 6 | 2023 | 102 | 1.910 |
Why?
|
| Medication Adherence | 9 | 2022 | 72 | 1.690 |
Why?
|
| Humans | 71 | 2023 | 25692 | 1.400 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 77 | 1.390 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 80 | 1.380 |
Why?
|
| Child | 26 | 2022 | 1277 | 1.350 |
Why?
|
| Community Health Workers | 6 | 2022 | 30 | 1.290 |
Why?
|
| Administration, Inhalation | 13 | 2022 | 34 | 1.220 |
Why?
|
| Behavior Therapy | 2 | 2017 | 79 | 1.010 |
Why?
|
| Caregivers | 7 | 2019 | 187 | 0.960 |
Why?
|
| Adolescent | 20 | 2023 | 2076 | 0.940 |
Why?
|
| Nebulizers and Vaporizers | 8 | 2022 | 19 | 0.920 |
Why?
|
| Pandemics | 9 | 2022 | 227 | 0.910 |
Why?
|
| Mobile Applications | 2 | 2020 | 29 | 0.820 |
Why?
|
| Biological Products | 1 | 2022 | 39 | 0.750 |
Why?
|
| Environmental Exposure | 2 | 2018 | 17 | 0.700 |
Why?
|
| Emergency Service, Hospital | 7 | 2020 | 245 | 0.700 |
Why?
|
| Allergy and Immunology | 4 | 2020 | 5 | 0.700 |
Why?
|
| Poverty | 3 | 2020 | 92 | 0.680 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 1077 | 0.670 |
Why?
|
| Betacoronavirus | 4 | 2020 | 65 | 0.650 |
Why?
|
| Adult | 19 | 2023 | 7336 | 0.640 |
Why?
|
| Parents | 2 | 2018 | 117 | 0.620 |
Why?
|
| Emigrants and Immigrants | 2 | 2018 | 20 | 0.610 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 37 | 0.600 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 6 | 0.600 |
Why?
|
| Health Literacy | 4 | 2021 | 96 | 0.600 |
Why?
|
| Registries | 1 | 2019 | 170 | 0.590 |
Why?
|
| Female | 28 | 2023 | 14273 | 0.540 |
Why?
|
| Decision Making | 1 | 2018 | 203 | 0.530 |
Why?
|
| Male | 27 | 2023 | 13917 | 0.520 |
Why?
|
| Child, Preschool | 8 | 2022 | 640 | 0.510 |
Why?
|
| Assertiveness | 1 | 2015 | 8 | 0.510 |
Why?
|
| Urban Population | 5 | 2013 | 149 | 0.470 |
Why?
|
| Chicago | 6 | 2019 | 869 | 0.440 |
Why?
|
| Family | 3 | 2021 | 94 | 0.430 |
Why?
|
| Bronchodilator Agents | 3 | 2022 | 19 | 0.420 |
Why?
|
| United States | 8 | 2023 | 1943 | 0.420 |
Why?
|
| House Calls | 3 | 2021 | 20 | 0.390 |
Why?
|
| Electronics | 2 | 2021 | 11 | 0.380 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 32 | 0.370 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 98 | 0.370 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 277 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 164 | 0.340 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 201 | 0.340 |
Why?
|
| Hospitalization | 3 | 2022 | 292 | 0.320 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2009 | 1 | 0.320 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 15 | 0.320 |
Why?
|
| Minority Groups | 3 | 2019 | 82 | 0.300 |
Why?
|
| Athletes | 1 | 2009 | 77 | 0.300 |
Why?
|
| MP3-Player | 1 | 2008 | 2 | 0.300 |
Why?
|
| Communication Barriers | 1 | 2007 | 4 | 0.290 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 156 | 0.290 |
Why?
|
| Quality Improvement | 3 | 2018 | 132 | 0.290 |
Why?
|
| Language | 1 | 2007 | 65 | 0.280 |
Why?
|
| Research Design | 2 | 2019 | 188 | 0.270 |
Why?
|
| Immunization, Passive | 2 | 2023 | 10 | 0.250 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 913 | 0.240 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 69 | 0.230 |
Why?
|
| Albuterol | 4 | 2022 | 14 | 0.230 |
Why?
|
| Middle Aged | 8 | 2022 | 8403 | 0.220 |
Why?
|
| One Health | 1 | 2023 | 1 | 0.220 |
Why?
|
| Self Care | 4 | 2020 | 90 | 0.210 |
Why?
|
| Patient Preference | 1 | 2023 | 28 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 27 | 0.210 |
Why?
|
| Health Status Disparities | 1 | 2023 | 65 | 0.210 |
Why?
|
| Glucocorticoids | 2 | 2020 | 68 | 0.210 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 3 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 18 | 0.200 |
Why?
|
| Vaccination | 1 | 2022 | 31 | 0.200 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 45 | 0.200 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 143 | 0.200 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 49 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2022 | 3231 | 0.190 |
Why?
|
| Anaphylaxis | 1 | 2021 | 9 | 0.190 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 847 | 0.190 |
Why?
|
| Endpoint Determination | 1 | 2021 | 21 | 0.190 |
Why?
|
| Biomedical Technology | 1 | 2021 | 8 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 107 | 0.180 |
Why?
|
| Mental Health | 2 | 2020 | 111 | 0.180 |
Why?
|
| Feedback | 1 | 2020 | 33 | 0.180 |
Why?
|
| Depression | 3 | 2020 | 412 | 0.180 |
Why?
|
| Clinical Coding | 1 | 2020 | 4 | 0.180 |
Why?
|
| Comparative Effectiveness Research | 2 | 2021 | 6 | 0.180 |
Why?
|
| Computer Security | 1 | 2020 | 5 | 0.180 |
Why?
|
| Self-Management | 2 | 2017 | 14 | 0.180 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 15 | 0.180 |
Why?
|
| Tiotropium Bromide | 1 | 2020 | 2 | 0.180 |
Why?
|
| Self Report | 1 | 2021 | 204 | 0.180 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2020 | 4 | 0.180 |
Why?
|
| Desensitization, Immunologic | 1 | 2020 | 3 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 209 | 0.170 |
Why?
|
| Lung | 1 | 2021 | 159 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 24 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 39 | 0.170 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 2 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2020 | 75 | 0.170 |
Why?
|
| Family Relations | 1 | 2019 | 14 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2019 | 183 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 138 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 149 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 13 | 0.160 |
Why?
|
| Documentation | 1 | 2019 | 25 | 0.160 |
Why?
|
| Pediatrics | 1 | 2019 | 38 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 70 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2018 | 16 | 0.150 |
Why?
|
| Patient Participation | 1 | 2018 | 42 | 0.150 |
Why?
|
| Prevalence | 2 | 2018 | 435 | 0.150 |
Why?
|
| Volunteers | 1 | 2017 | 4 | 0.140 |
Why?
|
| Community Participation | 1 | 2017 | 17 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 2224 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2017 | 26 | 0.140 |
Why?
|
| Cell Phone | 1 | 2017 | 3 | 0.140 |
Why?
|
| Education, Distance | 1 | 2017 | 18 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2016 | 22 | 0.140 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 16 | 0.130 |
Why?
|
| Smartphone | 1 | 2015 | 15 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3220 | 0.120 |
Why?
|
| Health Status | 3 | 2021 | 209 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 450 | 0.120 |
Why?
|
| Double-Blind Method | 2 | 2022 | 396 | 0.110 |
Why?
|
| Housing | 1 | 2013 | 19 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2021 | 618 | 0.110 |
Why?
|
| Animals | 2 | 2023 | 3510 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 163 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 600 | 0.100 |
Why?
|
| Young Adult | 4 | 2022 | 1855 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 290 | 0.100 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2012 | 6 | 0.100 |
Why?
|
| Aged | 3 | 2022 | 8501 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 311 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2013 | 403 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2017 | 392 | 0.100 |
Why?
|
| School Health Services | 1 | 2011 | 20 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 126 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 716 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 64 | 0.090 |
Why?
|
| Students | 1 | 2011 | 46 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2011 | 28 | 0.090 |
Why?
|
| Consensus | 2 | 2021 | 90 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2022 | 68 | 0.090 |
Why?
|
| Anti-Allergic Agents | 1 | 2010 | 2 | 0.090 |
Why?
|
| Androstadienes | 1 | 2010 | 5 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 7 | 0.090 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 5 | 0.090 |
Why?
|
| Acetates | 1 | 2010 | 16 | 0.090 |
Why?
|
| Anxiety | 2 | 2021 | 150 | 0.080 |
Why?
|
| Allergens | 2 | 2023 | 14 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 32 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2019 | 72 | 0.080 |
Why?
|
| Disease Progression | 2 | 2022 | 664 | 0.080 |
Why?
|
| Logistic Models | 2 | 2019 | 366 | 0.070 |
Why?
|
| Music | 1 | 2008 | 17 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2021 | 34 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 15 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2008 | 148 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2019 | 11 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1633 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2023 | 17 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 12 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 48 | 0.050 |
Why?
|
| Irritants | 1 | 2023 | 1 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 69 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 68 | 0.050 |
Why?
|
| Puerto Rico | 2 | 2013 | 10 | 0.050 |
Why?
|
| Dry Powder Inhalers | 1 | 2022 | 3 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 49 | 0.050 |
Why?
|
| Metered Dose Inhalers | 1 | 2022 | 4 | 0.050 |
Why?
|
| Patients | 1 | 2022 | 32 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 212 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 261 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 44 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2022 | 103 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 9 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 12 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 24 | 0.050 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 87 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2021 | 116 | 0.040 |
Why?
|
| London | 1 | 2020 | 2 | 0.040 |
Why?
|
| Terbutaline | 1 | 2020 | 1 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 52 | 0.040 |
Why?
|
| Self Administration | 1 | 2020 | 20 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 3 | 0.040 |
Why?
|
| Professionalism | 1 | 2020 | 4 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 29 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2020 | 8 | 0.040 |
Why?
|
| Guilt | 1 | 2020 | 5 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 20 | 0.040 |
Why?
|
| Suicide | 1 | 2020 | 13 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 19 | 0.040 |
Why?
|
| Social Support | 1 | 2021 | 188 | 0.040 |
Why?
|
| Grief | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 124 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 33 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 70 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 325 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 39 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 73 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 103 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 74 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 332 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 129 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 45 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 136 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 119 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 59 | 0.040 |
Why?
|
| Health Promotion | 1 | 2020 | 140 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 165 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 244 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 271 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 457 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 80 | 0.040 |
Why?
|
| Persuasive Communication | 1 | 2017 | 1 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 1689 | 0.030 |
Why?
|
| Sinusitis | 1 | 2019 | 144 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 39 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 71 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 111 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2016 | 91 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2013 | 5 | 0.030 |
Why?
|
| Enkephalin, Methionine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Saliva | 1 | 2013 | 57 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 46 | 0.030 |
Why?
|
| Vital Signs | 1 | 2012 | 3 | 0.030 |
Why?
|
| Work of Breathing | 1 | 2012 | 6 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2012 | 36 | 0.020 |
Why?
|
| Spirometry | 1 | 2012 | 11 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 207 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 187 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 124 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 211 | 0.020 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2010 | 1 | 0.020 |
Why?
|
| Sulfides | 1 | 2010 | 11 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2010 | 13 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2010 | 27 | 0.020 |
Why?
|
| Illinois | 1 | 2009 | 223 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 419 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 472 | 0.010 |
Why?
|
| Vietnam | 1 | 1993 | 7 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 157 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 256 | 0.010 |
Why?
|
| Alcoholism | 1 | 1993 | 65 | 0.010 |
Why?
|
| Veterans | 1 | 1993 | 75 | 0.010 |
Why?
|